Heart Valve Disease | CHOP Research Institute
 

Heart Valve Disease

‘Catalytic Funding’ Establishes the Topolewski Pediatric Heart Valve Center

Published on
May 18, 2023
in Cornerstone Blog
Multimillion-dollar Gift Establishes the Topolewski Pediatric Heart Valve Center
A multimillion-dollar gift from the Topolewski’s will further advance both clinical and basic science research at CHOP to treat pediatric heart valve disease.

Does Serotonin Contribute to Heart Valve Disease Progression in Patients With Low Serotonin Transport Activity?

Published on
Feb 13, 2023
in Cornerstone Blog
Does Serotonin Contribute to Heart Valve Disease Progression in Patients With Low Serotonin Transport Activity?
Researchers explore how serotonin may affect the heart’s mitral valve and potentially accelerate degenerative mitral regurgitation.

Can Durability, Longevity of Bioprosthetic Heart Valves be Improved?

Published on
Feb 25, 2022
in Cornerstone Blog
Modifying Bioprosthetic Heart Valves With Polymer Can Improve Durability
Structural degeneration of bioprosthetic heart valves can be prevented, according to new study from the Center for Pediatric Heart Valve Disorders.

Levy Laboratory

Levy Laboratory

Research in the Levy Lab centers on the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine.

Frontier Program Aims to Address Daunting Challenges of Heart Valve Disorders

Published on
Jan 26, 2021
in Cornerstone Blog
2021 Frontier Program: Center for Pediatric Heart Valve Disorders
Multidisciplinary team takes a coordinated approach to treat valve diseases and expand the existing knowledge of these complex conditions.
Robert J. Levy, MD
Robert J. Levy Headshot

Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.

E-mail:
levyr [at] chop.edu